Claims
- 1. Compounds of formula (I): ##STR8## wherein: R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom or a methyl group;
- R.sup.3 is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;
- X.sup.1 is a hydrogen atom, a methyl group, a methoxy group, a methanesulfonyl group, a halogen atom, a trifluoromethyl group, a nitro group or a cyano group at the 7-, 8-, or 9-position;
- X.sup.2 is a hydrogen atom;
- n is 1 or 2; and
- m is 0 or 1;
- and pharmaceutically acceptable acid addition salts thereof;
- excluding those compounds in which:
- R.sup.1, R.sup.2, R.sup.3, X.sup.1 and X.sup.2 all represent hydrogen atoms, n is 1 and m is 0; and
- R.sup.1, R.sup.2 and X.sup.2 all represent hydrogen atoms, R.sup.3 represents a hydrogen atom or a methyl group, X.sup.1 represents a chlorine atom at the 9-position, n is 1 and m is 0.
- 2. Compounds as claimed in claim 1, wherein:
- R.sup.1, R.sup.2 and R.sup.3 are the same or different and each represents a hydrogen atom or a methyl group;
- X.sup.1 is a methyl group, a methanesulfonyl group, a halogen atom, trifluoromethyl group, a nitro group or a cyano group at the 7-, 8- or 9-position;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 0 or 1.
- 3. Compounds as claimed in claim 1, wherein:
- R.sup.1 and R.sup.3 are the same or different and each represents a hydrogen atom or a methyl group;
- R.sup.2 represents a methyl group;
- X.sup.1 represents a substituent at the 8-position, said substituent being selected from a methanesulfonyl group, a halogen atom, a trifluoromethyl group, a nitro group or a cyano group;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 0 or 1.
- 4. Compounds as claimed in claim 1, wherein:
- R.sup.1, R.sup.2 and R.sup.3 all represent hydrogen atoms;
- X.sup.1 represents a hydrogen atom, a methoxy group, or a halogen atom at the 7- or 8-position;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 1.
- 5. 1,3,4,6-Tetrahydro-8-methanesulphonyl-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 6. 8-Fluoro-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 7. 8-Chloro-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 8. 8-Chloro-1,3,4,6-tetrahydro-3,6-dimethyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 9. 8-Chloro-1,3,4,6-tetrahydro-1,6-dimethyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 10. 8-Bromo-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 11. 1,3,4,6-Tetrahydro-8-iodo-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 12. 1,3,4,6-Tetrahydro-6-methyl-8-trifluoromethyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 13. 1,3,4,6-Tetrahydro-6-methyl-8-nitro-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 14. 8-Cyano-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine and its hydrochloride of the formula of claim 1.
- 15. 1,3,4,6-Tetrahydro-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 16. 8-Fluoro-1,3,4,6-tetrahydro-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 17. 8-Chloro-1,3,4,6-tetrahydro-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 18. 8-Bromo-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 19. 1,3,4,6-Tetrahydro-8-trifluoromethyl-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 20. 1,3,4,6-Tetrahydro-8-nitro-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 21. 8-Cyano-1,3,4,6-tetrahydro-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 22. 1,3,4,6-Tetrahydro-8-methoxy-2H-5,1-benzothiazocine-S-oxide of the formula of claim 1.
- 23. 9-Chloro-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine of the formula of claim 1.
- 24. 7-Chloro-1,3,4,6-tetrahydro-6-methyl-2H-5,1-benzothiazocine of the formula of claim 1.
- 25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or a diluent and, as active ingredient, a compound of formula (I): ##STR9## wherein: R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom or a methyl group;
- R.sup.3 is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;
- X.sup.1 is a hydrogen atom, a methyl group, a methoxy group, a methanesulfonyl group, a halogen atom, a trifluoromethyl group, a nitro group or a cyano group at the 7-, 8- or 9-position;
- X.sup.2 is a hydrogen atom;
- n is 1 or 2; and
- m is 0 or 1;
- or a pharmaceutically acceptable acid addition salt thereof;
- excluding those compounds in which:
- R.sup.1, R.sup.2, R.sup.3, X.sup.1 and X.sup.2 all represent hydrogen atoms, n is 1 and m is 0; and
- R.sup.1, R.sup.2 and X.sup.2 all represent atoms, R.sup.3 represents a hydrogen atom or a methyl group, X.sup.1 represents a chlorine atom at the 9-position, n is 1 and m is 0.
- 26. A composition as claimed in claim 25, wherein:
- R.sup.1, R.sup.2 and R.sup.3 are the same or different and each represents a hydrogen atom or a methyl group;
- X.sup.1 is a methyl group, a methanesulfonyl group, a halogen atom, trifluoromethyl group, a nitro group or a cyano group at the 7-, 8- or 9-position;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 0 or 1.
- 27. A composition as claimed in claim 25, wherein:
- R.sup.1 and R.sup.3 are the same or different and each represents a hydrogen atom or a methyl group;
- R.sup.2 represents a methyl group;
- X.sup.1 represents a substituent at the 8-position, said substituent being selected from a methanesulfonyl group, a halogen atom, a trifluoromethyl group, a nitro group or a cyano group;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 0 or 1.
- 28. A composition as claimed in claim 25, wherein
- R.sup.1, R.sup.2 and R.sup.3 all represent hydrogen atoms;
- X.sup.1 represents a hydrogen atom, a methoxy group, or a halogen atom at the 7- or 8-position;
- X.sup.2 represents a hydrogen atom;
- n is 1; and
- m is 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
53-67368 |
Jun 1978 |
JPX |
|
53-67369 |
Jun 1978 |
JPX |
|
Parent Case Info
This is a continuation of application Ser. No. 44,377 filed June 1, 1979, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3463774 |
Wenner et al. |
Aug 1969 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
44377 |
Jun 1979 |
|